SCHEMBL18889253

SCHEMBL18889253

O=C(O)c1ccc(-c2cccc3sc(C(=O)N4CCOCC4)cc23)cc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 11/20 0.78
L3MBTL1 Q9Y468 1/20 0.55
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPC1 O15118 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
PDCD1 Q15116 1/20 0.45
CD274 Q9NZQ7 1/20 0.45
HTR2C P28335 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18889198 0.91 RIPK1 (0.81) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889229 0.90 RIPK1 (0.77) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889288 0.89 RIPK1 (0.81) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889266 0.88 RIPK1 (1.00) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889214 0.88 RIPK1 (0.80) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889228 0.88 RIPK1 (0.80) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889262 0.85 RIPK1 (0.78) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889275 0.85 RIPK1 (0.75) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL20895155 0.85 RIPK1 (0.75) RIPK1L3MBTL1ALDH1A1POLBHPGD
SCHEMBL18889284 0.85 RIPK1 (0.75) RIPK1L3MBTL1ALDH1A1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP claimed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP claimed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US claimed
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP disclosed
EP-3176163-B1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT IAC IN NAT UNIV CHUNGNAM (KR) 2019-04-17 EP disclosed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP disclosed
EP-3176163-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT The Industry & Academic Cooperation in Chungnam National University (IAC) (KR) 2017-06-07 EP disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT MOTHER'S PHARMACEUTICAL CO., LTD. (KR) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152268-A1 NOVEL INDENE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT RIPK1, RIPK2, RIPK3 RIPK1 1/4885L3MBTL1 2632/4885ALDH1A1 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.